Press Release

Printer Friendly VersionView printer-friendly version << Back

Protagonist Therapeutics to Participate in the Barclay's Global Healthcare Conference

NEWARK, Calif., March 1, 2018Protagonist Therapeutics, Inc. (NASDAQ: PTGX) today announced that Dinesh V. Patel, Ph.D., the company's President and Chief Executive Officer, will provide a corporate overview on Thursday March 15 at the Barclay's Global Healthcare Conference. The conference will be held at the Loews Miami Beach Hotel in Miami Beach, Florida.

The Protagonist Therapeutics presentation is scheduled for 11:15 am Eastern Time and will be followed by a 25 minute Q&A breakout session at 11:45 am ET.

A live audio webcast of the presentation may be accessed by visiting the Investors page of Protagonist Therapeutics corporate website at A replay of the presentation will be available for 30 days following the presentation.

About Protagonist Therapeutics

Protagonist Therapeutics is a clinical development-stage biopharmaceutical company that utilizes a proprietary technology platform to discover and develop novel peptide-based drugs to transform existing treatment paradigms for patients with significant unmet medical needs. Its primary focus is to develop potential first-in-class oral gastrointestinal (GI) restricted targeted therapies that block validated biological pathways currently targeted by marketed injectable antibody drugs. Our lead peptide candidates, PTG-100 and PTG-200, are oral targeted therapy drugs being developed for inflammatory bowel diseases (IBD). The alpha-4-beta-7 integrin antagonist peptide PTG-100 is currently in a Phase 2b clinical trial for moderate-to-severe ulcerative colitis, and the company's interleukin-23 receptor antagonist peptide PTG-200 is currently being studied in a Phase 1 clinical trial in healthy volunteers to support further development in Crohn's disease.  Both alpha-4-beta-7 integrin and IL-12/23 pathway blockade are approaches that have been validated through FDA-approved injectable antibody drugs. The company has entered into a worldwide license and collaboration agreement with Janssen Biotech for the clinical development of PTG-200.  Protagonist has also applied its versatile platform outside of the GI disease areas and is developing an injectable hepcidin mimetic, PTG-300, for the potential treatment of rare blood diseases such as beta-thalassemia and myelodysplastic syndromes (MDS). PTG-300 recently completed a Phase 1 clinical trial where we achieved a pharmacodynamic-based clinical proof-of-concept in normal healthy volunteers.

Protagonist is headquartered in Newark, California with pre-clinical and clinical staff in California, and discovery operations both in California and Brisbane, Queensland, Australia. For further information, please visit



Cision View original content with multimedia:

SOURCE Protagonist Therapeutics, Inc.

Joan Kureczka, Bioscribe, Inc., Tel: +1 415-821-2413, Mobile: +1 415-690-0210, email:, For Investors: The Trout Group, Marcy Nanus, 646-378-2927,